Page 1391 - Williams Hematology ( PDFDrive )

1366 Part X: Malignant Myeloid Diseases Chapter 87: Myelodysplastic Syndromes 1367

226. Helder J, Deisseroth A: S1 nuclease analysis of alpha-globin gene expression in preleu- 256. Epling-Burnette PK, Painter JS, Rollison DE, et al: Prevalence and clinical association of
kemic patients with acquired hemoglobin H disease after transfer to mouse erythroleu- clonal T-cell expansions in myelodysplastic syndrome. Leukemia 21(4):659–667, 2007.
kemia cells. Proc Natl Acad Sci U S A 84(8):2387–2390, 1987. 257. Mufti GJ, Figes A, Hamblin TJ, et al: Immunological abnormalities in myelodysplastic
227. Anagnou NP, Ley TJ, Chesbro B, et al: Acquired alpha-thalassemia in preleukemia is syndromes. I. Serum immunoglobulins and autoantibodies. Br J Haematol 63(1):143–
due to decreased expression of all four alpha-globin genes. Proc Natl Acad Sci U S A 147, 1986.
80(19):6051–6055, 1983. 258. Economopoulos T, Economidou J, Giannopoulos G, et al: Immune abnormalities in
228. French registry of acute leukemia and myelodysplastic syndromes. Age distribution myelodysplastic syndromes. J Clin Pathol 38(8):908–911, 1985.
and hemogram analysis of the 4496 cases recorded during 1982–1983 and classified 259. Gatto S, Ball G, Onida F, et al: Contribution of beta-2 microglobulin levels to the prog-
according to FAB criteria. Groupe Francais de Morphologie Hematologique. Cancer nostic stratification of survival in patients with myelodysplastic syndrome (MDS).
60(6):1385–1394, 1987. Blood 102(5):1622–1625, 2003.
229. Friedland ML, Ward H, Wittels EG, Arlin ZA: A monocytic leukemoid reaction: A 260. Yue G, Hao S, Fadare O, et al: Hypocellularity in myelodysplastic syndrome is an inde-
manifestation of preleukemia. R I Med J 68(4):173–174, 1985. pendent factor which predicts a favorable outcome. Leuk Res 32(4):553–558, 2008.
230. Jaworkowsky LI, Solovey DY, Rhausova LY, Udris OY: Monocytosis as a sign of subse- 261. Delacretaz F, Schmidt PM, Piguet D, et al: Histopathology of myelodysplastic syn-
quent leukemia in patients with cytopenias (preleukemia). Folia Haematol Int Mag Klin dromes. The FAB classification (proposals) applied to bone marrow biopsy. Am J Clin
Morphol Blutforsch 110(3):395–401, 1983. Pathol 87(2):180–186, 1987.
231. Economopoulos T, Stathakis N, Maragoyannis Z, et al: Myelodysplastic syndrome. 262. Fohlmeister I, Fischer R, Modder B, et al: Aplastic anaemia and the hypocellular myel-
Clinical and prognostic significance of monocyte count, degree of blastic infiltration, odysplastic syndrome: Histomorphological, diagnostic, and prognostic features. J Clin
and ring sideroblasts. Acta Haematol 65(2):97–102, 1981. Pathol 38(11):1218–1224, 1985.
232. Shetty VT, Mundle SD, Raza A: Pseudo Pelger-Huet anomaly in myelodysplastic syn- 263. Kuriyama K, Tomonaga M, Matsuo T, et al: Diagnostic significance of detecting pseu-
drome: Hyposegmented apoptotic neutrophil? Blood 98(4):1273–1275, 2001. do-Pelger-Huet anomalies and micro-megakaryocytes in myelodysplastic syndrome.
233. Langenhuijsen MM: Neutrophils with ring-shaped nuclei in myeloproliferative disease. Br J Haematol 63(4):665–669, 1986.
Br J Haematol 58(2):227–230, 1984. 264. Mangi MH, Mufti GJ: Primary myelodysplastic syndromes: Diagnostic and prognos-
234. Linman JW, Bagby C Jr: The preleukemic syndrome: Clinical and laboratory features, tic significance of immunohistochemical assessment of bone marrow biopsies. Blood
natural course, and management. Nouv Rev Fr Hematol Blood Cells 17(1–2):11–31, 79(1):198–205, 1992.
1976. 265. Tricot G, De Wolf-Peeters C, Vlietinck R, Verwilghen RL: Bone marrow histology in
235. Clark RE, Smith SA, Jacobs A: Myeloid surface antigen abnormalities in myelodys- myelodysplastic syndromes. II. Prognostic value of abnormal localization of immature
plasia: Relation to prognosis and modification by 13-cis retinoic acid. J Clin Pathol precursors in MDS. Br J Haematol 58(2):217–225, 1984.
40(6):652–656, 1987. 266. Della Porta MG, Malcovati L, Boveri E, et al: Clinical relevance of bone marrow fibrosis
236. Cech P, Markert M, Perrin LH: Partial myeloperoxidase deficiency in preleukemia. Blut and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol
47(1):21–30, 1983. 27(5):754–762, 2009.
237. Schofield KP, Stone PC, Kelsey P, et al: Quantitative cytochemistry of blood neutrophils 267. Bellamy WT, Richter L, Sirjani D, et al: Vascular endothelial cell growth factor is an
in myelodysplastic syndromes and chronic granulocytic leukaemia. Cell Biochem Funct autocrine promoter of abnormal localized immature myeloid precursors and leukemia
1(2):92–96, 1983. progenitor formation in myelodysplastic syndromes. Blood 97(5):1427–1434, 2001.
238. Elghetany MT, Peterson B, MacCallum J, et al: Deficiency of neutrophilic granule mem- 268. Matsushima T, Handa H, Yokohama A, et al: Prevalence and clinical characteristics
brane glycoproteins in the myelodysplastic syndromes: A common deficiency in 216 of myelodysplastic syndrome with bone marrow eosinophilia or basophilia. Blood
patients studied by the Cancer and Leukemia Group B. Leuk Res 21(9):801–806, 1997. 101(9):3386–3390, 2003.
239. Prodan M, Tulissi P, Perticarari S, et al: Flow cytometric assay for the evaluation of 269. Queisser W, Queisser U, Ansmann M, et al: Megakaryocyte polyploidization in acute
phagocytosis and oxidative burst of polymorphonuclear leukocytes and monocytes in leukaemia and preleukaemia. Br J Haematol 28(2):261–270, 1974.
myelodysplastic disorders. Haematologica 80(3):212–218, 1995. 270. Smith WB, Ablin A, Goodman JR, Brecher G: Atypical megakaryocytes in preleukemic
240. Piva E, De Toni S, Caenazzo A, et al: Neutrophil NADPH oxidase activity in chronic phase of acute myeloid leukemia. Blood 42(4):535–540, 1973.
myeloproliferative and myelodysplastic diseases by microscopic and photometric 271. Bartl R, Frisch B, Baumgart R: Morphologic classification of the myelodysplastic syn-
assays. Acta Haematol 94(1):16–22, 1995. dromes (MDS): Combined utilization of bone marrow aspirates and trephine biopsies.
241. Ruutu P: Granulocyte function in myelodysplastic syndromes. Scand J Haematol Suppl Leuk Res 16(1):15–33, 1992.
45:66–70, 1986. 272. Della Porta MG, Travaglino E, Boveri E, et al: Minimal morphological criteria for defin-
242. Carulli G, Sbrana S, Minnucci S, et al: Actin polymerization in neutrophils from ing bone marrow dysplasia: A basis for clinical implementation of WHO classification
patients affected by myelodysplastic syndromes—A flow cytometric study. Leuk Res of myelodysplastic syndromes. Leukemia 20(10):161, 2014.
21(6):513–518, 1997. 273. Maschek H, Georgii A, Kaloutsi V, et al: Myelofibrosis in primary myelodysplastic syn-
243. Nakaseko C, Asai T, Wakita H, et al: Signalling defect in FMLP-induced neutrophil dromes: A retrospective study of 352 patients. Eur J Haematol 48(4):208–214, 1992.
respiratory burst in myelodysplastic syndromes. Br J Haematol 95(3):482–488, 1996. 274. Moehler TM, Ho AD, Goldschmidt H, Barlogie B: Angiogenesis in hematologic malig-
244. Payne CM, Glasser L: An ultrastructural morphometric analysis of platelet giant and nancies. Crit Rev Oncol Hematol 45(3):227–244, 2003.
fusion granules. Blood 67(2):299–309, 1986. 275. Ribatti D, Polimeno G, Vacca A, et al: Correlation of bone marrow angiogenesis
245. Pamphilon DH, Aparicio SR, Roberts BE, et al: The myelodysplastic syndromes—A and mast cells with tryptase activity in myelodysplastic syndromes. Leukemia 16(9):
study of haemostatic function and platelet ultrastructure. Scand J Haematol 33(5): 1680–1684, 2002.
486–491, 1984. 276. Della Porta MG, Malcovati L, Rigolin GM, et al: Immunophenotypic, cytogenetic and
246. Rasi V, Lintula R: Platelet function in the myelodysplastic syndromes. Scand J Haematol functional characterization of circulating endothelial cells in myelodysplastic syn-
Suppl 45:71–73, 1986. dromes. Leukemia 22(3):530–537, 2008.
247. Hamblin TJ: Immunological abnormalities in myelodysplastic syndromes. Semin 277. Lobe I, Rigal-Huguet F, Vekhoff A, et al: Myelodysplastic syndrome after acute promyelo-
Hematol 33(2):150–162, 1996. cytic leukemia: The European APL group experience. Leukemia 17(8):1600–1604, 2003.
248. Anderson RW, Volsky DJ, Greenberg B, et al: Lymphocyte abnormalities in preleukemia—I. 278. Smith SM, Le Beau MM, Huo D, et al: Clinical-cytogenetic associations in 306 patients
Decreased NK activity, anomalous immunoregulatory cell subsets and deficient EBV recep- with therapy-related myelodysplasia and myeloid leukemia: The University of Chicago
tors. Leuk Res 7(3):389–395, 1983. series. Blood 102(1):43–52, 2003.
249. Kerndrup G, Meyer K, Ellegaard J, Hokland P: Natural killer (NK)-cell activity and 279. Krishnan A, Bhatia S, Slovak ML, et al: Predictors of therapy-related leukemia and mye-
antibody-dependent cellular cytotoxicity (ADCC) in primary preleukemic syndrome. lodysplasia following autologous transplantation for lymphoma: An assessment of risk
Leuk Res 8(2):239–247, 1984. factors. Blood 95(5):1588–1593, 2000.
250. Takagi S, Kitagawa S, Takeda A, et al: Natural killer-interferon system in patients with 280. Abruzzese E, Radford JE, Miller JS, et al: Detection of abnormal pretransplant clones in
preleukaemic states. Br J Haematol 58(1):71–81, 1984. progenitor cells of patients who developed myelodysplasia after autologous transplan-
251. Volsky DJ, Anderson RW: Deficiency in Epstein-Barr virus receptors on B-lymphocytes tation. Blood 94(5):1814–1819, 1999.
of preleukemia patients. Cancer Res 43(8):3923–3926, 1983. 281. Van Den Neste E, Louviaux I, Michaux JL, et al: Myelodysplastic syndrome with mono-
252. Baumann MA, Milson TJ, Patrick CW, et al: Immunoregulatory abnormalities in mye- somy 5 and/or 7 following therapy with 2-chloro-2′-deoxyadenosine. Br J Haematol
lodysplastic disorders. Am J Hematol 22(1):17–26, 1986. 105(1):268–270, 1999.
253. Knox SJ, Greenberg BR, Anderson RW, Rosenblatt LS: Studies of T-lymphocytes in 282. Rigolin GM, Cuneo A, Roberti MG, et al: Exposure to myelotoxic agents and myelodys-
preleukemic disorders and acute nonlymphocytic leukemia: In vitro radiosensitivity, plasia: Case-control study and correlation with clinicobiological findings. Br J Haema-
mitogenic responsiveness, colony formation, and enumeration of lymphocytic subpop- tol 103(1):189–197, 1998.
ulations. Blood 61(3):449–455, 1983. 283. Sterkers Y, Preudhomme C, Lai JL, et al: Acute myeloid leukemia and myelodysplastic
254. Lawrence HJ, Broudy VC, Magenis RE, et al: Cytogenetic evidence for involvement of syndromes following essential thrombocythemia treated with hydroxyurea: High pro-
B lymphocytes in acquired idiopathic sideroblastic anemias. Blood 70(4):1003–1005, portion of cases with 17p deletion. Blood 91(2):616–622, 1998.
1987. 284. Park DJ, Koeffler HP: Therapy-related myelodysplastic syndromes. Semin Hematol
255. Meers S, Vandenberghe P, Boogaerts M, et al: The clinical significance of activated 33(3):256–273, 1996.
lymphocytes in patients with myelodysplastic syndromes: A single centre study of 131 285. Karp JE, Sarkodee-Adoo CB: Therapy-related acute leukemia. Clin Lab Med 20(1):
patients. Leuk Res 32(7):1026–1035, 2008. 71–81, ix, 2000.

Kaushansky_chapter 87_p1341-1372.indd 1366 9/21/15 11:06 AM